Biomarkers in cancer immunotherapy

Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay syst...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer cell Ročník 27; číslo 1; s. 12
Hlavní autoři: Schumacher, Ton N, Kesmir, Can, van Buuren, Marit M
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 12.01.2015
Témata:
Antibodies, Neoplasm - therapeutic use
Biomarkers, Tumor - genetics
Biomarkers, Tumor - immunology
Humans
Immunotherapy - methods
Neoplasms - genetics
Neoplasms - immunology
T-Lymphocytes - immunology
ISSN:1878-3686, 1878-3686
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1878-3686
1878-3686
DOI:10.1016/j.ccell.2014.12.004